FilingSEC EDGAR6-K
Eupraxia Pharmaceuticals Announces 52-Week Data from Phase 1b/2a Trial of EP-104GI
· SEC accepted
StagePhase 1b/2a
Filing content
Eupraxia Pharmaceuticals announced 52-week clinical data from its Phase 1b/2a trial of EP-104GI for eosinophilic esophagitis, demonstrating sustained clinical remission and tolerability.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…